Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides

Circulation. 2005 Jun 14;111(23):3095-104. doi: 10.1161/CIRCULATIONAHA.104.510594. Epub 2005 Jun 6.

Abstract

Background: Although disruption of guanylyl cyclase (GC) A, a natriuretic peptide receptor, induces cardiac hypertrophy and fibrosis, the molecular mechanism underlying these effects are not well understood. In this study, we examined the role of calcineurin, a calcium-dependent phosphatase, in cardiac remodeling in GCA-knockout (GCA-KO) mice.

Methods and results: At 14 weeks of age, calcineurin activity, nuclear translocation of nuclear factor of activated T cells c3 (NFATc3), and modulatory calcineurin-interacting protein 1 (MCIP1) gene expressions were increased in the hearts of GCA-KO mice compared with wild-type (WT) mice. Blockade of calcineurin activation by FK506 (6 mg/kg body weight administered subcutaneously once a day from 10 to 14 weeks of age) significantly decreased the heart-to-body weight ratio, cardiomyocyte size, and collagen volume fraction in GCA-KO mice, whereas FK506 did not affect these parameters in WT mice. Overexpression of atrial and brain natriuretic peptides, collagen, and fibronectin mRNAs in GCA-KO mice was also attenuated by FK506. Electrophoretic mobility shift assays demonstrated that GATA4 DNA-binding activity was increased in GCA-KO mice, and this increase was inhibited by calcineurin blockade. In neonatal cultured cardiac myocytes, inhibition of GCA by HS142-1 (100 microg/mL) increased basal and phenylephrine (10(-6) mol/L)-stimulated calcineurin activity, nuclear translocation of NFATc3, and MCIP1 mRNA expression. In contrast, activation of GCA by atrial natriuretic peptide (10(-6) mol/L) inhibited phenylephrine (10(-6) mol/L)-stimulated nuclear translocation of NFATc3.

Conclusions: These results suggest that activation of cardiac GCA by locally secreted natriuretic peptides protects the heart from excessive cardiac remodeling by inhibiting the calcineurin-NFAT pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atrial Natriuretic Factor / genetics
  • Atrial Natriuretic Factor / metabolism
  • Atrial Natriuretic Factor / physiology*
  • Calcineurin / metabolism*
  • Calcineurin Inhibitors
  • Cardiomegaly / etiology*
  • Cardiomegaly / pathology
  • DNA-Binding Proteins
  • Enzyme Activation
  • Fibrosis / etiology
  • Gene Expression Regulation / drug effects
  • Guanylate Cyclase / deficiency*
  • Guanylate Cyclase / metabolism
  • Intracellular Signaling Peptides and Proteins
  • Mice
  • Mice, Knockout
  • Muscle Proteins / genetics
  • Muscle Proteins / physiology
  • Myocardium / metabolism
  • NFATC Transcription Factors / genetics
  • NFATC Transcription Factors / metabolism*
  • Natriuretic Peptide, Brain / genetics
  • Natriuretic Peptide, Brain / metabolism
  • Natriuretic Peptide, Brain / physiology*
  • RNA, Messenger / analysis
  • Receptors, Atrial Natriuretic Factor / deficiency*
  • Receptors, Atrial Natriuretic Factor / metabolism
  • Tacrolimus / administration & dosage
  • Tacrolimus / pharmacology

Substances

  • Calcineurin Inhibitors
  • DNA-Binding Proteins
  • Intracellular Signaling Peptides and Proteins
  • Muscle Proteins
  • NFATC Transcription Factors
  • NFATC3 protein, human
  • RCAN1 protein, human
  • RNA, Messenger
  • Natriuretic Peptide, Brain
  • Atrial Natriuretic Factor
  • Calcineurin
  • Guanylate Cyclase
  • Receptors, Atrial Natriuretic Factor
  • atrial natriuretic factor receptor A
  • Tacrolimus